Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Senior Vice President | December 14, 2011 | December 16, 2011 |
| ALIMERA SCIENCES INCALIM · Entity 11664 | Director | June 18, 2020 | June 22, 2020 |
| Absci CorpABSI · Entity 4685 | Director | June 30, 2026 | July 06, 2026 |
| Averin Capital Acquisition Corp.ACAAU · Entity 5761 | Director | February 18, 2026 | February 18, 2026 |
| Coherus Oncology, Inc.CHRS · Entity 6276 | Director | January 11, 2021 | January 13, 2021 |
| Kura Oncology, Inc.KURA · Entity 4871 | Director | June 04, 2026 | June 04, 2026 |
| NOVELION THERAPEUTICS INC.NVLN · Entity 152369 | Director · Chief Executive Officer | May 09, 2017 | May 11, 2017 |
| Omega Therapeutics, Inc.OMGA · Entity 83618 | Director | June 20, 2024 | June 21, 2024 |
| TriSalus Life Sciences, Inc.TLSI · Entity 5872 | Director · CEO and President | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date December 14, 2011 · Filed December 16, 2011
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 119,342 |
Ending reported balance
After 2011-12-14 transaction · row 27
27 source rows · reconciled sequenceRow 1 · 2011-12-14 · Exercise / conversion · Acquired 53,201 · Balance 172,543 Row 2 · 2011-12-14 · Sale · Disposed 500 · Balance 172,043 Row 3 · 2011-12-14 · Sale · Disposed 300 · Balance 171,743 Row 4 · 2011-12-14 · Sale · Disposed 2,500 · Balance 169,243 Row 5 · 2011-12-14 · Sale · Disposed 200 · Balance 169,043 Row 6 · 2011-12-14 · Sale · Disposed 100 · Balance 168,943 Row 7 · 2011-12-14 · Sale · Disposed 900 · Balance 168,043 Row 8 · 2011-12-14 · Sale · Disposed 1,550 · Balance 166,493 Row 9 · 2011-12-14 · Sale · Disposed 2,100 · Balance 164,393 Row 10 · 2011-12-14 · Sale · Disposed 2,100 · Balance 162,293 Row 11 · 2011-12-14 · Sale · Disposed 100 · Balance 162,193 Row 12 · 2011-12-14 · Sale · Disposed 900 · Balance 161,293 Row 13 · 2011-12-14 · Sale · Disposed 5,500 · Balance 155,793 Row 14 · 2011-12-14 · Sale · Disposed 5,195 · Balance 150,598 Row 15 · 2011-12-14 · Sale · Disposed 1,600 · Balance 148,998 Row 16 · 2011-12-14 · Sale · Disposed 100 · Balance 148,898 Row 17 · 2011-12-14 · Sale · Disposed 1,900 · Balance 146,998 Row 18 · 2011-12-14 · Sale · Disposed 3,700 · Balance 143,298 Row 19 · 2011-12-14 · Sale · Disposed 4,500 · Balance 138,798 Row 20 · 2011-12-14 · Sale · Disposed 2,300 · Balance 136,498 Row 21 · 2011-12-14 · Sale · Disposed 5,275 · Balance 131,223 Row 22 · 2011-12-14 · Sale · Disposed 2,488 · Balance 128,735 Row 23 · 2011-12-14 · Sale · Disposed 212 · Balance 128,523 Row 24 · 2011-12-14 · Sale · Disposed 2,700 · Balance 125,823 Row 25 · 2011-12-14 · Sale · Disposed 3,200 · Balance 122,623 Row 26 · 2011-12-14 · Sale · Disposed 2,781 · Balance 119,842 Row 27 · 2011-12-14 · Sale · Disposed 500 · Balance 119,342 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.63 · Expires 2012-02-14 | Direct | 0 |
Reported balance
After 2011-12-14 transaction · row 29
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 29 · 2011-12-14 · Exercise / conversion · Disposed 53,201 · Balance 0 F2: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 80 |
Reported balance
Holding disclosure · report date 2011-12-14 · row 28
Holding and transaction disclosures are not merged.
1 source rowRow 28 · Balance 80 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of December 14, 2011. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of December 14, 2011.
F2: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3.
ALIMERA SCIENCES INC
Report date June 18, 2020 · Filed June 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.70 · Expires 2030-06-17 | Direct | 3,333 |
Reported balance
After 2020-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-18 · Grant · Acquired 3,333 · Balance 3,333 F1: Vests in equal monthly installments over 12 months starting one month after the grant date (June 18, 2020), provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests in equal monthly installments over 12 months starting one month after the grant date (June 18, 2020), provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date.
Absci Corp
Report date June 30, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,300 |
Reported balance
After 2026-06-30 transaction · row 1
1 source rowRow 1 · 2026-06-30 · Purchase · Acquired 12,900 · Balance 21,300 F1: Open market purchase of shares in accordance with Issuer's trading policies. |
Filing footnotes · ownership attribution and instrument terms
F1: Open market purchase of shares in accordance with Issuer's trading policies.
Averin Capital Acquisition Corp.
Report date February 18, 2026 · Filed February 18, 2026
This filing explicitly reported no securities owned.
Coherus Oncology, Inc.
Report date January 11, 2021 · Filed January 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.58 · Expires 2031-01-11 | Direct | 20,000 |
Reported balance
After 2021-01-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-11 · Grant · Acquired 20,000 · Balance 20,000 F1: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Kura Oncology, Inc.
Report date June 04, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $8.77 · Expires 2036-06-03 | Direct | 35,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 35,000 · Balance 35,000 F1: This option vests in full on the one year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in full on the one year anniversary of the date of grant.
NOVELION THERAPEUTICS INC.
Report date May 09, 2017 · Filed May 11, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 6,632 |
Reported balance
After 2017-05-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-05-09 · Exercise / conversion · Acquired 6,632 · Balance 6,632 F1: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016. F2: Each restricted stock unit represents a contingent right to receive one common share. |
| Common SharesSEC Table I · non-derivative | Direct | 4,384 |
Reported balance
After 2017-05-09 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2017-05-09 · Tax withholding · Disposed 2,248 · Balance 4,384 F3: The shares reported as disposed were withheld by the Issuer to satisfy tax withholding obligations of the Reporting Person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 13,264 |
Reported balance
After 2017-05-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-05-09 · Exercise / conversion · Disposed 6,632 · Balance 13,264 F2: Each restricted stock unit represents a contingent right to receive one common share. F1: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016. F4: 33.34% of the grant vested on May 9, 2017. Subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or one of its affiliates, 33.33% of the grant will vest on May 9, 2018 and 33.33% of the grant will vest on May 9, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016.
F2: Each restricted stock unit represents a contingent right to receive one common share.
F3: The shares reported as disposed were withheld by the Issuer to satisfy tax withholding obligations of the Reporting Person.
F4: 33.34% of the grant vested on May 9, 2017. Subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or one of its affiliates, 33.33% of the grant will vest on May 9, 2018 and 33.33% of the grant will vest on May 9, 2019.
Omega Therapeutics, Inc.
Report date June 20, 2024 · Filed June 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.20 · Expires 2034-06-19 | Direct | 25,000 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 25,000 · Balance 25,000 F1: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.
TriSalus Life Sciences, Inc.
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,074,990 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Tax withholding · Disposed 2,693 · Balance 1,074,990 F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units previously granted. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units previously granted.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aegerion Pharmaceuticals, Inc.
Report date November 29, 2016 · Filed December 01, 2016
Section 16 reporting ended · disclosed 2016-12-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.65 · Expires 2026-01-07 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-11-29 · Disposition to issuer · Disposed 600,000 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective on November 29, 2016, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 (the "Exchange Ratio") by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc." ("Novelion"). F1: 25% of the shares of common stock underlying this stock option award were to vest on January 7, 2017. The remaining 75% of the shares of common stock underlying this stock option award were to vest thereafter in equal monthly installments through January 7, 2020, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.46 · Expires 2026-05-09 | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-11-29 · Disposition to issuer · Disposed 194,000 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective on November 29, 2016, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 (the "Exchange Ratio") by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc." ("Novelion"). F3: 25% of the shares of common stock underlying this stock option award were to vest on May 9, 2017. The remaining 75% of the shares of common stock underlying this stock option award were to vest thereafter in equal monthly installments through May 9, 2020, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2016-11-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-11-29 · Disposition to issuer · Disposed 97,000 · Balance 0 F4: Each restricted stock unit represented a contingent right to receive one share of common stock. F6: Pursuant to the Merger Agreement, each restricted stock unit with respect to common stock of the Issuer ("Aegerion RSU") that was outstanding as of immediately prior to the effective time of the merger was exchanged for a restricted stock unit ("Novelion RSU") with respect to a number of common shares of Novelion equal to the product obtained by multiplying (i) the total number of shares of common stock of the Issuer subject to the Aegerion RSU immediately prior to the effective time of the merger by (ii) the Exchange Ratio. Each Novelion RSU is subject to the same terms and conditions applicable to the corresponding Aegerion RSU and the agreements evidencing grant of the Aegerion RSUs thereunder, including vesting terms, but excluding any terms that are rendered inoperative solely by reason of the merger. F5: The restricted stock units were to vest in three annual installments, with 33.34% of the units scheduled to vest on May 9, 2017, 33.33% of the units scheduled to vest on May 9, 2018 and 33.33% of the units scheduled to vest on May 9, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares of common stock underlying this stock option award were to vest on January 7, 2017. The remaining 75% of the shares of common stock underlying this stock option award were to vest thereafter in equal monthly installments through January 7, 2020, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.
F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective on November 29, 2016, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 (the "Exchange Ratio") by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc." ("Novelion").
F3: 25% of the shares of common stock underlying this stock option award were to vest on May 9, 2017. The remaining 75% of the shares of common stock underlying this stock option award were to vest thereafter in equal monthly installments through May 9, 2020, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.
F4: Each restricted stock unit represented a contingent right to receive one share of common stock.
F5: The restricted stock units were to vest in three annual installments, with 33.34% of the units scheduled to vest on May 9, 2017, 33.33% of the units scheduled to vest on May 9, 2018 and 33.33% of the units scheduled to vest on May 9, 2019, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.
F6: Pursuant to the Merger Agreement, each restricted stock unit with respect to common stock of the Issuer ("Aegerion RSU") that was outstanding as of immediately prior to the effective time of the merger was exchanged for a restricted stock unit ("Novelion RSU") with respect to a number of common shares of Novelion equal to the product obtained by multiplying (i) the total number of shares of common stock of the Issuer subject to the Aegerion RSU immediately prior to the effective time of the merger by (ii) the Exchange Ratio. Each Novelion RSU is subject to the same terms and conditions applicable to the corresponding Aegerion RSU and the agreements evidencing grant of the Aegerion RSUs thereunder, including vesting terms, but excluding any terms that are rendered inoperative solely by reason of the merger.
Prometheus Biosciences, Inc.
Report date June 16, 2023 · Filed June 16, 2023
Section 16 reporting ended · disclosed 2023-06-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 1
1 source rowRow 1 · 2023-06-16 · Disposition to issuer · Disposed 2,071 · Balance 0 F1: Reflects restricted stock units. F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.00 · Expires 2031-03-10 | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-16 · Disposition to issuer · Disposed 40,000 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.02 · Expires 2032-05-18 | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-16 · Disposition to issuer · Disposed 20,500 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects restricted stock units.
F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3)
F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 7, 2026 20:02 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | Tax withholdingCommon Stock | 2,693 | $4.38 | $11,795.34 |
DisclosureSEC source: 0001628280-26-065323 · wk-form4_1791403347.xml · nonDerivative · entry 1 Szela Mary T · CIK 0001410289 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,074,990 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units previously granted. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:04 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 3,990 | $3.87 | $15,441.30 |
DisclosureSEC source: 0001628280-26-046519 · wk-form4_1782936285.xml · nonDerivative · entry 1 Szela Mary T · CIK 0001410289 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,077,683 F1 · shares: Represents shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| June 30, 2026 Filed Jul 6, 2026 20:06 UTC | Absci Corp ABSI · Entity 4685 | PurchaseCommon Stock | 12,900 | $11.54 | $148,866.00 |
DisclosureSEC source: 0001672688-26-000124 · wk-form4_1783368371.xml · nonDerivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,300 F1 · shares: Open market purchase of shares in accordance with Issuer's trading policies. Read SEC document |
| June 04, 2026 Filed Jun 4, 2026 22:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 35,000 | $0.00 Strike: $8.77 | $0.00 |
DisclosureSEC source: 0001193125-26-257897 · ownership.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-06-03 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 01:59 UTC | Absci Corp ABSI · Entity 4685 | GrantStock Option (right to buy) · Derivative | 39,800 | $0.00 Strike: $7.34 | $0.00 |
DisclosureSEC source: 0001470831-26-000526 · wk-form4_1780970353.xml · derivative · entry 2 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,800 Underlying: Common Stock · 39,800 shares Expires 2036-06-03 F2 · derivative.exercise_date: The shares subject to this option vest and become exercisable in full on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 01:59 UTC | Absci Corp ABSI · Entity 4685 | GrantCommon Stock | 10,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000526 · wk-form4_1780970353.xml · nonDerivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,100 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Absci Corporation 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest and be settled in full on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document |
| June 04, 2026 Filed Jun 16, 2026 00:40 UTC Amendment | Absci Corp ABSI · Entity 4685 | GrantStock Option (right to buy) · Derivative | 33,200 | $0.00 Strike: $7.34 | $0.00 |
DisclosureSEC source: 0001672688-26-000116 · wk-form4a_1781570428.xml · derivative · entry 2 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,200 Underlying: Common Stock · 33,200 shares Expires 2036-06-03 F2 · derivative.exercise_date: The shares subject to this option vest and become exercisable in full on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document |
| June 04, 2026 Filed Jun 16, 2026 00:40 UTC Amendment | Absci Corp ABSI · Entity 4685 | GrantCommon Stock | 8,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001672688-26-000116 · wk-form4a_1781570428.xml · nonDerivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,400 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Absci Corporation 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest and be settled in full on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:42 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 39,682 | $2.59 | $102,776.38 |
DisclosureSEC source: 0001628280-26-035994 · wk-form4_1779136946.xml · nonDerivative · entry 1 Szela Mary T · CIK 0001410289 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,065,215 F1 · kind: The Reporting Person's purchase of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 39,682 shares at a weighted average price of $2.59, with the Reporting Person's sales of 4,358 shares of common stock at a price per share of $4.13 on March 11, 2026 and of 15,944 shares of common stock at a price per share of $3.85. The prior sales represented shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person, and did not represent discretionary sales by the Reporting Person. The Reporting Person paid $27,573.70 to the Issuer, representing the full amount of profit realized in connection with the short-swing transaction. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.48 to $2.62 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| March 17, 2026 Filed Mar 20, 2026 20:25 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | SaleCommon Stock | 15,944 | $3.85 | $61,384.40 |
DisclosureSEC source: 0001628280-26-020186 · wk-form4_1774038323.xml · nonDerivative · entry 2 Szela Mary T · CIK 0001410289 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 752,987 F1 · shares: Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This transaction does not represent a discretionary sale by the reporting person. Read SEC document |
| March 11, 2026 Filed Mar 20, 2026 20:25 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | SaleCommon Stock | 4,358 | $4.13 | $17,998.54 |
DisclosureSEC source: 0001628280-26-020186 · wk-form4_1774038323.xml · nonDerivative · entry 1 Szela Mary T · CIK 0001410289 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 768,931 F1 · shares: Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This transaction does not represent a discretionary sale by the reporting person. Read SEC document |
| February 23, 2026 Filed Feb 23, 2026 21:08 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 30,487 | $4.10 | $124,996.70 |
DisclosureSEC source: 0001628280-26-010603 · wk-form4_1771880883.xml · nonDerivative · entry 1 Szela Mary T · CIK 0001410289 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 773,289 Read SEC document |
| December 31, 2025 Filed Jul 1, 2026 20:03 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 2,100 | $4.38 | $9,198.00 |
DisclosureSEC source: 0001628280-26-046511 · wk-form5_1782936210.xml · nonDerivative · entry 3 Szela Mary T · CIK 0001410289 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,023,826 F1 · shares: Represents shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 20:55 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $5.55 | $0.00 |
DisclosureSEC source: 0001410289-25-000006 · wk-form4_1764104104.xml · derivative · entry 4 Szela Mary T · CIK 0001410289 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,578,182 Underlying: Common Stock · 250,000 shares Expires 2035-11-23 F4 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of November 24, 2025 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD (or if there is no corresponding day, on the last day of the month), subject to continued employment through the respective vesting date. Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 20:55 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001410289-25-000006 · wk-form4_1764104104.xml · nonDerivative · entry 3 Szela Mary T · CIK 0001410289 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 742,802 F3 · shares: Represents the granting of PSUs upon achieving or exceeding $75 million of revenue over any 12 consecutive calendar month period ending on or before December 31, 2027. 150,000 PSUs vest immediately upon achieving the performance requirement and 150,000 PSUs vest on the one-year anniversary of achieving the performance requirement, subject to the continued employment through each respective vesting date. Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 20:55 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001410289-25-000006 · wk-form4_1764104104.xml · nonDerivative · entry 2 Szela Mary T · CIK 0001410289 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 442,802 F2 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on November 24, 2025, subject to continued employment through the respective vesting date. Read SEC document |
| July 07, 2025 Filed Jul 9, 2025 20:46 UTC | Absci Corp ABSI · Entity 4685 | GrantStock Option (right to buy) · Derivative | 178,400 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001628280-25-034662 · wk-form4_1752093997.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,400 Underlying: Common Stock · 178,400 shares Expires 2035-07-06 F1 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 36 approximately equal monthly installments from July 7, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 30, 2025 Filed Jul 1, 2026 20:03 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 2,848 | $4.23 | $12,047.04 |
DisclosureSEC source: 0001628280-26-046511 · wk-form5_1782936210.xml · nonDerivative · entry 2 Szela Mary T · CIK 0001410289 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 596,726 F1 · shares: Represents shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 20:05 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 28,500 | $0.00 Strike: $6.57 | $0.00 |
DisclosureSEC source: 0000950170-25-083035 · ownership.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 28,500 shares Expires 2035-06-04 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 22:41 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 21,089 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004682 · form4-02192025_100243.xml · nonDerivative · entry 1 Szela Mary T · CIK 0001410289 · Director · CEO AND PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 465,348 F1 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award shall vest on February 13, 2026, subject to the Reporting Person's continued service with the Issuer on such vesting date. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 22:54 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 5,010 | $5.28 | $26,452.80 |
DisclosureSEC source: 0001415889-25-002536 · form4-01312025_100135.xml · nonDerivative · entry 2 Szela Mary T · CIK 0001410289 · Director · CEO AND PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 444,259 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.15 to $5.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 22:54 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 5,030 | $5.03 | $25,300.90 |
DisclosureSEC source: 0001415889-25-002536 · form4-01312025_100135.xml · nonDerivative · entry 1 Szela Mary T · CIK 0001410289 · Director · CEO AND PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 439,249 Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 23:15 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 4,716 | $5.12 | $24,145.92 |
DisclosureSEC source: 0001415889-25-002292 · form4-01292025_110101.xml · nonDerivative · entry 3 Szela Mary T · CIK 0001410289 · Director · CEO AND PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,219 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.03 to $5.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 23:15 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantEmployee Stock Option (right to buy) · Derivative | 240,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001415889-25-002292 · form4-01292025_110101.xml · derivative · entry 4 Szela Mary T · CIK 0001410289 · Director · CEO AND PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2035-01-26 F4 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of January 1, 2025 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD (or if there is no corresponding day, on the last day of the month), subject to the Reporting Person's continuous service with the Issuer on each respective vesting date. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 23:15 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 4,826 | $5.42 | $26,156.92 |
DisclosureSEC source: 0001415889-25-002292 · form4-01292025_110101.xml · nonDerivative · entry 2 Szela Mary T · CIK 0001410289 · Director · CEO AND PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 429,503 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.25 to $5.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 23:15 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002292 · form4-01292025_110101.xml · nonDerivative · entry 1 Szela Mary T · CIK 0001410289 · Director · CEO AND PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 424,677 F1 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on January 1, 2025, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
| December 31, 2024 Filed Jul 1, 2026 20:03 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 3,530 | $4.26 | $15,037.80 |
DisclosureSEC source: 0001628280-26-046511 · wk-form5_1782936210.xml · nonDerivative · entry 1 Szela Mary T · CIK 0001410289 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 513,207 F1 · shares: Represents shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| September 13, 2024 Filed Sep 13, 2024 21:43 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 6,000 | $5.00 | $30,000.00 |
DisclosureSEC source: 0001415889-24-023390 · form4-09132024_090910.xml · nonDerivative · entry 3 Szela Mary T · CIK 0001410289 · Director · CEO AND PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 384,677 Read SEC document |
| September 13, 2024 Filed Sep 13, 2024 21:43 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 1,295 | $4.83 | $6,254.85 |
DisclosureSEC source: 0001415889-24-023390 · form4-09132024_090910.xml · nonDerivative · entry 2 Szela Mary T · CIK 0001410289 · Director · CEO AND PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 378,677 Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:43 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 7,520 | $5.20 | $39,104.00 |
DisclosureSEC source: 0001415889-24-023390 · form4-09132024_090910.xml · nonDerivative · entry 1 Szela Mary T · CIK 0001410289 · Director · CEO AND PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 377,382 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.05 to $5.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| September 10, 2024 Filed Sep 12, 2024 23:06 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 5,000 | $4.97 | $24,850.00 |
DisclosureSEC source: 0001415889-24-023320 · form4-09122024_110917.xml · nonDerivative · entry 1 Szela Mary T · CIK 0001410289 · Director · CEO AND PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 369,862 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.91 to $4.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 16:20 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0000950170-24-076267 · ownership.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 26,000 | $0.00 Strike: $21.79 | $0.00 |
DisclosureSEC source: 0000950170-24-070702 · ownership.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2034-06-04 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| February 13, 2024 Filed Feb 14, 2024 23:44 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantEmployee Stock Option (right to buy) · Derivative | 288,750 | $0.00 Strike: $9.40 | $0.00 |
DisclosureSEC source: 0001415889-24-003821 · form4-02142024_110233.xml · derivative · entry 2 Szela Mary T · CIK 0001410289 · Director · CEO AND PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 288,750 Underlying: Common Stock · 288,750 shares Expires 2034-02-12 F2 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of February 13, 2024, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
| February 13, 2024 Filed Feb 14, 2024 23:44 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 84,899 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-003821 · form4-02142024_110233.xml · nonDerivative · entry 1 Szela Mary T · CIK 0001410289 · Director · CEO AND PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,862 F1 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on February 13, 2024, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
| February 13, 2024 Filed Nov 25, 2025 20:55 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001410289-25-000006 · wk-form4_1764104104.xml · nonDerivative · entry 1 Szela Mary T · CIK 0001410289 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 317,802 F1 · shares: Represents the granting of Performance Stock Units (PSUs) upon achieving or exceeding $50 million of revenue over any 12 consecutive calendar month period ending on or before February 28, 2027. The PSUs vest immediately upon achieving the performance requirement, subject to the continued employment through each respective vesting date. Read SEC document |
| August 14, 2023 Filed Aug 15, 2023 20:48 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantEmployee Stock Option (right to buy) · Derivative | 172,500 | $0.00 Strike: $11.51 | $0.00 |
DisclosureSEC source: 0001209191-23-045877 · doc4.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,500 Underlying: Common Stock · 172,500 shares Expires 2033-08-13 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date of August 10, 2023, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
| June 16, 2023 Filed Jun 16, 2023 20:00 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | Disposition to issuerStock Option (right to buy) · Derivative | 20,500 | Not disclosed Strike: $29.02 | Not disclosed |
DisclosureSEC source: 0000899243-23-015755 · doc4.xml · derivative · entry 3 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,500 shares Expires 2032-05-18 F2 · price: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3 · price: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3 · derivative.exercise_date: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. Read SEC document |
| June 16, 2023 Filed Jun 16, 2023 20:00 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | Disposition to issuerStock Option (right to buy) · Derivative | 40,000 | Not disclosed Strike: $19.00 | Not disclosed |
DisclosureSEC source: 0000899243-23-015755 · doc4.xml · derivative · entry 2 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2031-03-10 F2 · price: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3 · price: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3 · derivative.exercise_date: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. Read SEC document |
| June 16, 2023 Filed Jun 16, 2023 20:00 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | Disposition to issuerCommon Stock | 2,071 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-015755 · doc4.xml · nonDerivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Reflects restricted stock units. F2 · price: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3 · price: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 16:05 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantStock Option (Right to Buy) · Derivative | 18,118 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0000899243-23-015147 · doc4.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,118 Underlying: Common Stock · 18,118 shares Expires 2033-06-06 F1 · derivative.exercise_date: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 21:02 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 26,000 | $0.00 Strike: $13.32 | $0.00 |
DisclosureSEC source: 0001209191-23-033888 · doc4.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2033-05-30 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| May 19, 2023 Filed May 19, 2023 21:47 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | GrantCommon Stock | 2,071 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031193 · doc4.xml · nonDerivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,071 F1 · kind: Award of restricted stock units ("RSUs") granted under the Issuer's 2021 Incentive Award Plan (the "2021 Plan"). Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The RSUs shall vest in full upon the earlier to occur of (i) the first anniversary of the date of grant, (ii) the Issuer's next occurring annual meeting of stockholders, or (iii) a Change of Control (as defined in the 2021 Plan), subject to the Reporting Person's continued service with the Issuer on such vesting date. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 20:49 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 23,000 | $0.00 Strike: $14.84 | $0.00 |
DisclosureSEC source: 0001209191-22-038926 · doc4.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2032-06-20 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 16:10 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantOption (Right to Buy) · Derivative | 18,118 | $0.00 Strike: $3.31 | $0.00 |
DisclosureSEC source: 0000899243-22-021893 · doc4.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,118 Underlying: Common Stock · 18,118 shares Expires 2032-06-07 F1 · derivative.exercise_date: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| May 19, 2022 Filed May 20, 2022 23:30 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | GrantStock Option (Right to Buy) · Derivative | 20,500 | $0.00 Strike: $29.02 | $0.00 |
DisclosureSEC source: 0001209191-22-031178 · doc4.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2032-05-18 F1 · derivative.exercise_date: The shares subject to the option will vest in full upon the earlier to occur of (i) the first anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 21:19 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 23,000 | $0.00 Strike: $21.54 | $0.00 |
DisclosureSEC source: 0001209191-21-042788 · doc4.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2031-06-21 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 02:47 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001209191-21-020029 · doc4.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-03-10 F1 · derivative.exercise_date: The shares subject to the option will vest in substantially equal monthly installments over three years, commencing on March 17, 2021, subject to the Reporting Person's continued service with the Issuer through each vest date. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 21:29 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $17.58 | $0.00 |
DisclosureSEC source: 0001567619-21-000987 · doc1.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-01-11 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:10 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 23,000 | $0.00 Strike: $17.97 | $0.00 |
DisclosureSEC source: 0001209191-20-039074 · doc4.xml · derivative · entry 1 Szela Mary T · CIK 0001410289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.